Obesity

3 articles in this category

Tirzepatide Demonstrates Cardiovascular Safety and Emerging Neuroprotective Signals in Cardiometabolic Disease

Words by Yuriy Poteshkin, MD, phD

The dual GLP-1/GIP receptor agonist tirzepatide continued to demonstrate broad cardiometabolic benefits across multiple domains. The SURPASS-CVOT trial showed tirzepatide was noninferior to...

Dec 29, 2025Read more

tirzepatideGLP-1 agonistdiabetes

Weight-management “just-in-time” digital interventions: ML is present, but still not the default (single-paper signal)

Words by Yuriy Poteshkin, MD, phD

A scoping review this week maps the design space of just-in-time adaptive interventions (JITAIs) for adult weight management and highlights a reality check: only a minority of studies use...

Dec 28, 2025Read more

digital healthobesityjust-in-time adaptive interventions

Semaglutide’s footprint keeps widening (hospital use + insulin-sparing signals)

Words by Yuriy Poteshkin, MD, phD

Two semaglutide papers this week reinforce a shift from “weight-loss drug” to “systems-impact therapy.” In an exploratory SELECT analysis (obesity/overweight + established CVD, no diabetes)...

Dec 28, 2025Read more

emaglutideGLP-1 receptor agonistobesity